Shares of Athersys, which have nearly doubled in the past 3 months, should keep their momentum as a number of data points concerning the company's regenerative medicine treatments roll in, says Gil Van Bokkelen, CEO of Athersys. Van Bokkelen says the company's lead drug MultiStem is entering into a number of late stage clinical trials across a number of illnesses. He also says the company is making huge strides with patents in Japan and has successfully raised enough cash to carry it forward.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Alphabet, Coca-Cola, Caterpillar Reveal Earnings Season Will Be Awesome

Alphabet, Coca-Cola, Caterpillar Reveal Earnings Season Will Be Awesome

How Did Caterpillar Get Its Name?

How Did Caterpillar Get Its Name?

Alphabet's Earnings Beat and 4 Other Business Stories You Must Know Tuesday

Alphabet's Earnings Beat and 4 Other Business Stories You Must Know Tuesday

Wait, Google Was Almost Called What?

Wait, Google Was Almost Called What?

Video: Jim Cramer on Trade Tariffs, Rising Rates, Kimberly Clark and Hasbro

Video: Jim Cramer on Trade Tariffs, Rising Rates, Kimberly Clark and Hasbro